Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee

Annals of Oncology

Volumn 9, Issue 9, 1998, Pages 939-950

  Eisinger, F ^a   Alby, N ^b   Bremond, A ^c   Dauplat, J ^d   Espie M ^e   Janiaud, P ^f   Kuttenn, F ^g   Lebrun, J P ^h   Lefranc, J P ⁱ   Pierret, J ^f   Sobol, H ^a   Stoppa Lyonnet, D ^j   Thouvenin, D ^k   Tristant, H ^h   Feingold, J ^f  

^a INSTITUT PAOLI CALMETTES   (France)

^b National League Against Cancer   (France)

^c CENTRE LÉON BÉRARD   (France)

^d Jean Perrin Center   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f INSERM   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Salpétrière Hospital ^*

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j INSTITUT CURIE   (France)

^k UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

BRCA1; BRCA2; Breast cancer; Guidelines; Ovarian cancer; Preventive care

Indexed keywords

ESTROGEN; GESTAGEN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; DECISION MAKING; FRANCE; GENETIC EPIDEMIOLOGY; GENETIC SUSCEPTIBILITY; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; LAW; MASTECTOMY; ONCOGENE; ORGANIZATION; OVARIECTOMY; OVARY CANCER; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL;

EID: 7844223656     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008389021382     Document Type: Article

References (87)

1. Jonsen AR. Durfy SJ, Burke W, Motulsky AG. The advent of the 'unpatients'. Nature Med 1996; 2: 622-4.
2. Julian-Reynier C. Eisinger F, Vennin P et al. Attitudes towards cancer predictive testing and transmission of information to the family. J Med Genet 1996; 33: 731 6.
3. Etchells E, Sharpe G, Burgess MM, Singer PA. Bioethics for clinicians. 2. Disclosure. Can Med Assoc J 1996; 155: 387-91.
4. Morrow R, Bryant J. Health policy approaches to measuring and valuing human life: Conceptual and ethical issues. Am J Public Health 1995; 85: 1356-60.
5. Berman P. The study of macro and micro implementation. Publ Pol 1978; 26: 157-84.
6. Sobol H, Bignon Y-J, Cuisenier J et al. Le groupe Génétique et Cancer de la FNCLCC. Les consultations d'oncogénétique en 1994, analyse de l'activité: Enquête sur 203 consultations. In Boiron M (ed): Eurocancer 95. Paris: John Libbey Eurotext 1995: 43-6.
7. INSERM-FNCLCC. Risques Héréditaires de cancers du sein et de l'ovaire. Quelles prises en charge? Paris: INSERM 1998. Expertise Collective ed.
8. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-8.
9. Gayther S, Warren W, Mazoyer S et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet 1995; 11: 428-33.
10. Gayther S, Mangion J, Russell P et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genet 1997; 15: 103-5.
11. Claus E, Risch N, Thompson W. Autosomal dominant inheritance of early-onset breast cancer. Cancer 1993; 73: 643-51.
12. Berry D, Parmigiani G, Sanchez J, Schildkraut J. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997; 89: 227-38.
13. Lathrop G, Lalouel J, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci USA 1984; 81: 3443-6.
14. Sutherland HJ, Lockwood GA, Tritchler DL et al. Communicating probabilistic information to cancer patients: Is there 'noise' on the line? Soc Sci Med 1991; 32: 725-31.
15. Ford D, Easton DF, Bishop DT et al. and the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692-5.
16. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. Breast and Ovarian Cancer Incidence in BRCA1-Mutation carriers. Am J Hum Genet 1995; 56: 265-71.
17. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer suceptibility gene, BRCA2, to chromosome 13q12 13. Science 1994; 265: 2088-90.
18. Easton D, Bishop D, Ford D, Crockford G, consortium. Bcl. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 1993; 52: 678-701.
19. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. Jama 1997; 277: 997-1003.
20. Easton D, Narod S, Ford D, Steel M, on the behalf of the Breast Cancer Linkage Consortium. The genetic epidemiology of BRCA1. Lancet 1994; 344: 761.
21. INSERM, ed. Statistiques des causes médicales de décès 1994. Paris: Editions INSERM 1996. Statistiques de Santé.
22. Haut Comité de Santé Publique. La Santé en France. Annexes: Travaux des groupes thématiques. Paris: La Documentation Française 1994.
23. Claus EB, Schildkraut JM, Thompson JM, Risch NJ. The genetic attribuable risk of breast and ovarian cancer. Cancer 1996; 77: 2318-24.
24. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60: 496-504.
25. Kjaer SK, Storm HH. Survival of Danish cancer patients 1943 1987. Female genital organs. Apmis Suppl 1993; 33: 107 21.
26. Colditz G, Rosner B, Speizer F, Group FtNHSR. Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 1996; 88: 365 71.
27. Sobol H, Birnbaum D, Eisinger F. Evidence for a third breastcancer susceptibility gene. Lancet 1994; 344: 1151-2.
28. Ford D, Easton D, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 679-89.
29. Couch FJ, DeShano ML, Blackwood MA et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336: 1409 15.
30. Couch F, Farid L, DeShano M et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genet 1996; 13: 123 5.
31. Marcus J, Watson P, Page D, Lynch H. Pathology and hereditary of breast cancer in younger women. Monogr Natl Cancer Inst 1994; 16: 23 34.
32. Jacquemier J, Eisinger F, Birnbaum D, Sobol H. Histoprognostic grade in BRCA1 associated breast cancer. Lancet 1995; 345: 1503.
33. Eisinger F, Stoppa-Lyonnet D, Longy M et al. Germ-line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996; 56: 471-4.
34. Marcus J, Watson P, Page D et al. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697-709.
35. The Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505 10.
36. Porter D, Dixon M, Smyth E, Steel C. Breast cancer survival in BRCA1 carriers. Lancet 1993; 341: 184-5.
37. Malone KE, Daling JR, Weiss NS et al. Family history and survival of young women with invasive breast carcinoma. Cancer 1996; 78: 1417-25.
38. Rubin S, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335: 1413-6.
39. Ozcelik H, Schmocker B, Di Nicola N et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nature Genet 1997; 16: 17 18.
40. Collins F. Lots of Mutations, Lots of Dilemmas. N Engl J Med 1996; 334: 186 8.
41. Couch F. Weber B et al. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Human Mutai 1996; 8: 8-18.
42. Friend S, Borresen A, Brody L et al. Breast cancer information on the web. Nature Genet 1995; 11: 238-9.
43. Gayther S, Ponder B, Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. Mol Med Today 1997; 3: 168-74.
44. Serova O, Montagna M, Torchard D et al. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet 1996; 58: 42-51.
45. Mazoyer S, Dunning A, Serova O et al. A polymorphic stop codon in BRCA2. Nature Genet 1996; 14: 253-4.
46. Malone KE, Daling JR, Thompson JD et al. BRCA1 mutations and breast cancer in the general population. JAMA 1998; 379: 922-9.
47. Newman B, Mu H, Butler L et al. Frequency of breast cancer attribuable to BRCA1 in a population-based series of American women. JAMA 1998; 279: 915-21.
48. Sobol H. Stoppa-Lyonnet D, Bressac-de-Paillerets B et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res 1996; 56: 3216-9.
49. Julian-Reynier C, Eisinger F, Chabal F et al. Cancer genetic clinics: Target population and expectations. Eur J Cancer 1996; 32A (3): 398-403.
50. Nelson N. Caution guides genetic testing for hereditary cancer genes. J Natl Cancer Inst 1996; 88: 70-2.
51. Li FP. Translational research on hereditary colon, breast, and ovarian cancers. J Natl Cancer Inst Monogr 1995; 1995 (17): 1-4.
52. Biesecker BB, Garber JE. Testing and counseling adults for heritable cancer risk. J Natl Cancer Inst Monogr 1995; 1995 (17): 115-8.
53. Eisinger F, Thouvenin D, Bignon YJ et al. Réflexions sur l'organisation des consultations d'oncogénétique (première étape vers la publication de bonnes pratiques cliniques). Bull Cancer 1995; 82: 865-78.
54. Weber BL, Giusti RM, Liu ET. Developing strategies for intervention and prevention in hereditary breast cancer. J Natl Cancer Inst Monogr 1995; 1995 (17): 99 102.
55. The Ad Hoc Committe on Genetic Testing/Insurance Issues. Background statement genetic testing and insurance. Am J Hum Genet 1995; 56: 327-31.
56. Kash KM, Holland JC, Halper MS, Miller DG. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 1992; 84: 24-30.
57. Lerman C, Croyle RT. Genetic testing for cancer predisposition: Behavioral science issues. J Natl Cancer Inst Monogr 1995; 1995 (17): 63-6.
58. Geller G, Botkin J, Green M et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA 1997; 277: 1467-74.
59. Brown P, Ames N, Mettger W et al. Closing the comprehension gap: Low literacy and the Cancer Information Service. Monogr Natl Cancer Inst 1993; 1993 (14): 157-63.
60. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 117: 1038-41.
61. Colditz GA, Giovannucci E, Grodstein F et al. Oral contraceptive use and mortality during 12 years of follow-up: The nurses' health study. Ann Intern Med 1994; 120: 821-6.
62. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713 27.
63. Baghurst PA, Rohan TE. High-fiber diets and reduced risk of breast cancer. Intern J Cancer 1994; 56: 173 6.
64. Hunter D, Willett W. Diet, body size, and breast cancer. Epidemiol Rev 1993; 15: 110-31.
65. Ganz PA, Day R, Ware JJ et al. Base-line quality-of-life assessment in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Nail Cancer Inst 1995; 87: 1372-82.
66. Ault A, Bradbury J. Experts argue about tamoxifen prevention trial. Lancet 1998; 351: 1107.
67. Sherman B, Chapler F, Crickard K, Wycoff D. Endocrine consequence of continous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 1979; 64: 3984-404.
68. Auvinen A, Elovainio L, Hakama M. Breast self examination and survival from breast cancer. A prospective follow-up study. Breast Cancer Res Treat 1996; 38: 161-8.
69. Thomas D, Gao D, Self S et al. Randomized trial of breast self-examination in Shanghai: Methodology and preliminary result. J Natl Cancer Inst 1997; 89: 355-65.
70. Frank JW, Mai V. Breast self-examination in young women: More harm than good? Lancet 1985; 2: 654-7.
71. Hayward RSA, Steinberg EP, Ford DE et al. Preventive care guidelines 1991. Ann Intern Med 1991; 114: 758-83.
72. Vasen HF. Screening in breast cancer families: Is it useful? Ann Med 1994; 26: 185-90.
73. Den Otter W, Merchant T, Beijerinck, Koten J. Breast cancer induction due to mammographic screening in hereditary affected women. Anticancer Res 1996; 16: 3173-6.
74. Wald N, Murphy P, Major P et al. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. BMJ 1995; 311: 1189-93.
75. Thurfjell E, Lernevall K, Taube A. Benefit of independent double reading in a population-based mammography screening program. Radiology 1994; 191: 241-4.
76. Eyre H, Sondik E, Smith R, Kessler L. Communication from the American Cancer Society, the National Cancer Institute and the International Union Against Cancer. Joint meeting on the feasibility of a study of screening premenopausal women (40-49 years) for breast cancer: april 20+21 1994. Cancer 1995; 75: 1391-403.
77. Kerlikowske K, Grady D, Rubin S et al. Efficacy of screening mammography. A meta-analysis. J Am Med Assoc 1995; 273: 149-54.
78. Ziegler L, Kroll S. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991; 14: 451-4.
79. Biesecker BB, Boehnke M, Calzone K et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993; 269: 1970-4.
80. Nguyen M, Lairy G, Fleurette M. Les implants mammaires emplis de gel de silicone. Paris ANDEM 1996.
81. American College of Physicians. Screening for ovarian cancer: Recommendations and rationale. Ann Intern Med 1994; 121: 141-2.
82. Struewing JP, Watson P, Easton DF et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995; 1995 (17): 33-5.
83. Eisinger F, Julian-Reynier C, Chabal F et al. Acceptable strategies for dealing with hereditary breast/ovarian cancer risk. J Natl Cancer Inst 1997; 89: 731.
84. Casey M, Bewtra C, Garcia-Padial J, Lynch H. Laparascopic examination and assisted bilateral salpingo-oophorectomy hysterectomy for prophylactic removal of the ovaries and uterus in women at genetic risk for ovarian cancer. J Gynecol Tech 1995; 1: 111-4.
85. Salazar H, Godwin AK, Daly MB et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996; 88: 1810-20.
86. Jacquemier J, Eisinger F, Guinebretiere J et al. Intraductal component and BRCA1-associated breast cancer. Lancet 1996; 348: 1098.
87. Henderson I, Patek A. Are breast cancers in young women qualitatively distinct? Lancet 1997; 349: 1488-9.